HotSpot Therapeutics Presents Preclinical Data on Oral Small Molecule IRF5 Inhibitor HST‑2011 at ACR Convergence 2026
BOSTON, Nov. 9, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory pockets, today announced the presentation of preclinical data for HST‑2011, the Company's...